Sjögren's Syndrome in Progressive Systemic Sclerosis

  1. JAMES F. CIPOLETTI, M.D.;
  2. ROBERT B. BUCKINGHAM, M.D., F.A.C.P.;
  3. E. LEON BARNES, M.D.;
  4. ROBERT L. PEEL, M.D.;
  5. KHALID MAHMOOD, M.D.;
  6. FRANKLIN E. CIGNETTI, M.D.;
  7. JOHN M. PIERCE, M.D.;
  8. BRUCE S. RABIN, M.D.; and
  9. GERALD P. RODNAN, M.D., F.A.C.P.
  1. Pittsburgh, Pennsylvania

    Abstract

    Thirty-five consecutive patients with progressive systemic sclerosis were prospectively evaluated for evidence of Sjögren's syndrome. Six of the 35 (17%) were judged to have the disorder. This is a higher prevalence than in most reports, but much lower than that recently reported by Alarcón-Segovia and associates (7). An additional 17 of the 35 patients (48%) had significant fibrosis in the absence of sufficient mononuclear cell infiltrates to confirm the diagnosis of Sjögren's syndrome. This group had particularly aggressive scleroderma with serious visceral features, and five died after a short duration of illness. No significant abnormalities were found in biopsies from six patients with the mixed connective tissue disease syndrome, five with Raynaud's phenomenon alone, or in 29 autopsy control subjects who had no evidence of connective tissue disease. Fibrosis in the absence of mononuclear infiltration in minor salivary glands of patients with progressive systemic sclerosis indicates a poor prognosis.

    Article and Author Information

    • ▸From the Division of Rheumatology and Clinical Immunology, Department of Medicine, the Division of Immunopathology, and the Department of Pathology, University of Pittsburgh School of Medicine; and the Presbyterian-University Hospital; Pittsburgh, Pennsylvania.

    • ▸Requests for reprints should be addressed to Robert B. Buckingham, M.D.; Department of Medicine, University of Pittsburgh; Pittsburgh, PA 15261.

      • Received April 11, 1977.
      • Accepted August 8, 1977.
    « Previous | Next Article »Table of Contents